PDL BIOPHARMA, INC. 4
4 · PDL BIOPHARMA, INC. · Filed Oct 5, 2015
Insider Transaction Report
Form 4
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2015-09-29$4.95/sh+15,291$75,690→ 155,764 total
Footnotes (1)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2016; 16.66% on December 2017; 16.66% on December 2018; and 16.66% on December 2019.